Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

The promoter of the rat 5alpha-reductase type 1 gene is bidirectional and Sp1-dependent.

Authors:
Yannick Blanchard Shayesta Seenundun Bernard Robaire

Mol Cell Endocrinol 2007 Jan 27;264(1-2):171-83. Epub 2006 Dec 27.

Department of Pharmacology & Therapeutics, McGill University, Montréal, Québec, Canada.

In many androgen target tissues, testosterone is reduced to the more potent androgen, dihydrotestosterone, by steroid 5alpha-reductase. Two isoforms of 5alpha-reductase, type 1 and type 2, have been cloned. They are differentially expressed and regulated. To determine the mechanisms of regulation of 5alpha-reductase type 1 expression, we have cloned its 5'upstream region and defined its promoter. The proximal 5'upstream region of 5alpha-reductase type 1 displays all the features of a CpG island and has numerous Sp1 binding sites. By transient transfection assays, we have identified a bidirectional promoter activity in this region; this activity was highest in the negative orientation, in the direction of the methyltransferase Nsun2 (predicted) gene. Promoter activity, in either orientation, was lost in Sp1 deficient cells but was rescued following co-transfection with a Sp1 expression vector. Thus, the 5'upstream region of rat 5alpha-reductase type 1 contains a bidirectional promoter with an activity that is Sp1-dependent.

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.mce.2006.11.007DOI Listing
January 2007

Publication Analysis

Top Keywords

5alpha-reductase type
20
5'upstream region
12
promoter activity
12
bidirectional promoter
8
rat 5alpha-reductase
8
type
6
5alpha-reductase
6
promoter
5
transient transfection
4
sp1 binding
4
binding sites
4
sites transient
4
assays identified
4
activity
4
numerous sp1
4
identified bidirectional
4
transfection assays
4
displays features
4
promoter proximal
4
defined promoter
4

Keyword Occurance

Similar Publications

Extracts of Leaves Represses Human Steroid 5-Alpha Reductase Type 2 Promoter Activity in BHP-1 Cells and Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Rat Model.

Authors:
Kwang Hoon Song Chang-Seob Seo Won-Kyung Yang Hyun-O Gu Ki-Joong Kim Seung-Hyung Kim

Nutrients 2021 Mar 9;13(3). Epub 2021 Mar 9.

Institute of Traditional Medicine and Bioscience, Daejeon University, Daejeon 34520, Korea.

Benign prostatic hyperplasia (BPH) is the most common symptomatic abnormality of the human prostate characterized by uncontrolled proliferation of the prostate gland. In this study, we investigated the effect of bamboo, leaves extract (PPE) on human 5α-reductase type 2 (SRD5A2) gene promoter activity in human prostate cell lines and the protective effect of PPE on a testosterone-induced BPH rat model. PPE repressed human SRD5A2 promoter activity and its mRNA expression. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Male assignment in 5α-reductase type 2 deficiency with female external genitalia.

Authors:
Ayako Konishi Shinobu Ida Futoshi Matsui Yuri Etani Masanobu Kawai

Pediatr Int 2021 Mar 25. Epub 2021 Mar 25.

Department of Gastroenterology, Nutrition and Endocrinology, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan.

View Article and Full-Text PDF
March 2021
Similar Publications

Recent advances in pharmacological interventions of chronic prostatitis/chronic pelvic pain syndrome.

Authors:
Nasrin Aktar Ahmed Moudud Tingting Chen Xiaoqing Gao Hanhui Min Meng Tang Xiaohui Zhou

Curr Pharm Des 2021 Mar 22. Epub 2021 Mar 22.

Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198. China.

Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative void-ing, sexual dysfunction and pelvic pain. Chronic prostatitis/chronic pelvic pain syn-drome weakens the quality of life and poses adverse psychological effects on the pa-tients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phos-phodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal anti-body, anticholinergics, gabapentin, pregabalin are used clinically. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada.

Authors:
Michel D Wissing Ana O'Flaherty Alice Dragomir Simon Tanguay Wassim Kassouf Armen G Aprikian

Clin Genitourin Cancer 2021 Feb 6. Epub 2021 Feb 6.

Department of Surgery, McGill University Health Centre, Montreal, QC, Canada; Department of Oncology, McGill University, Montreal, QC, Canada.

Background: Existing literature suggests that bladder cancer (BC) outcome may be improved when patients use 5α-reductase inhibitors and/or α-blockers, but such a conclusion may be subject to publication bias. We evaluated whether preoperative use of 5α-reductase inhibitors or α-blockers was associated with improved clinical outcomes in a cohort of patients with BC undergoing radical cystectomy (RC).

Patients And Methods: Using provincial health administrative databases, we retrospectively identified male BC patients undergoing RC in Quebec province between 2000 and 2015, and we collected data from 2 years before RC until December 2016 or death. Read More

View Article and Full-Text PDF
February 2021
Similar Publications